Inclusion Criteria
o	Completion of informed consent prior to any study specific procedures 
o	Patients must agree to tissue collection for correlative studies at the specified timepoints 
o	Patients must consent to the MD Anderson Immunotherapy Platform laboratory protocol PA13-0291 
o	Male aged 18 years and above 
o	Histologically or cytologically confirmed prostate carcinoma 
o	Presence of metastatic disease documented on imaging studies (bone scan, computed tomography [CT] and/or magnetic resonance imaging [MRI] scans)
o	Patients must meet at least one of the following AVPC criteria:
•	Histologically proven small cell (neuroendocrine) prostate carcinoma

Exclusion Criteria
	Any prior treatment for castration-resistant prostate cancer (CRPC) with carboplatin, cisplatin, cabazitaxel, PARP-inhibitor or an anti-PD1 or anti-PDL1 inhibitor 
	Patients who have received more than one line of chemotherapy. Any number of prior hormonal or targeted therapies are allowed 
	Patients who have not recovered from adverse events secondary to systemic therapy (except for luteinizing hormone-releasing hormone [LHRH] agonist or antagonist treatment for prostate cancer, and bisphosphonates or RANK ligand inhibitors for bone strengthening), major surgery or radiotherapy for the treatment of prostate cancer to a grade =< 2 
	Any unresolved toxicity (Common Terminology Criteria for Adverse Events [CTCAE] grade >= 2) from previous anti-cancer therapy. Subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripherally neuropathy) 
	History or current diagnosis of MDS/AML
